ArticlePLoS genetics2008
Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes.
Article in PLoS genetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 80 citations in OpenAlex.
- Gene regulatory network analysis identifies auranofin as an anti-atherosclerotic drug.Nature communications · 2026Article
- HSDL2 Suppresses Epileptic Seizures Through Phosphorylation-Dependent Modulation of the PSD95-NMDAR Signaling Axis.CNS neuroscience & therapeutics · 2026Article
- Single-cell RNA sequencing reveals sex differences in the subcellular composition and associated gene-regulatory network activity of human carotid plaques.Nature cardiovascular research · 2025Article
- Precision cardiovascular medicine: shifting the innovation paradigm.Frontiers in science · 2025Article
- PIEZO1 targeting in macrophages boosts phagocytic activity and foam cell apoptosis in atherosclerosis.Cellular and molecular life sciences : CMLS · 2024Article
- Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis.Circulation research · 2024Article
- Bioinformatic analysis of short-chain dehydrogenase/reductase proteins in plant peroxisomes.Frontiers in plant science · 2023Article
- Connections for Matters of the Heart: Network Medicine in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022Review
- MicroRNA-146b-3p regulates the dysfunction of vascular smooth muscle cells via repressing phosphoinositide-3 kinase catalytic subunit gamma.Bioengineered · 2021Article
- Induction of the Coxsackievirus and Adenovirus Receptor in Macrophages During the Formation of Atherosclerotic Plaques.The Journal of infectious diseases · 2020Article
- Mendelian randomization while jointly modeling cis genetics identifies causal relationships between gene expression and lipids.Nature communications · 2020Article
- VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.EMBO reports · 2020Article
- About the existence of common determinants of gene expression in the porcine liver and skeletal muscle.BMC genomics · 2019Article
- Contribution of Gene Regulatory Networks to Heritability of Coronary Artery Disease.Journal of the American College of Cardiology · 2019Article
- Liver proteomics unravel the metabolic pathways related to Feed Efficiency in beef cattle.Scientific reports · 2019Article
- Integrating Genes Affecting Coronary Artery Disease in Functional Networks by Multi-OMICs Approach.Frontiers in cardiovascular medicine · 2018Review
- Circular RNA expression profiles of peripheral blood mononuclear cells in rheumatoid arthritis patients, based on microarray chip technology.Molecular medicine reports · 2017Article
- Omics-based approaches to understand mechanosensitive endothelial biology and atherosclerosis.Wiley interdisciplinary reviews. Systems biology and medicine · 2016Review
- Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases.Science (New York, N.Y.) · 2016Article
- Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease.Cell systems · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the well-documented effects of plasma lipid lowering regimes halting atherosclerosis lesion development and reducing morbidity and mortality of coronary artery disease and stroke, the transcriptional response in the atherosclerotic lesion mediating these beneficial effects has not yet been carefully investigated. We performed transcriptional profiling at 10-week intervals in atherosclerosis-prone mice with human-like hypercholesterolemia and a genetic switch to lower plasma lipoproteins (Ldlr(-/-)Apo(100/100)Mttp(flox/flox) Mx1-Cre). Atherosclerotic lesions progressed slowly at first, then expanded rapidly, and plateaued after advanced lesions formed. Analysis of lesion expression profiles indicated that accumulation of lipid-poor macrophages reached a point that led to the rapid expansion phase with accelerated foam-cell formation and inflammation, an interpretation supported by lesion histology. Genetic lowering of plasma cholesterol (e.g., lipoproteins) at this point all together prevented the formation of advanced plaques and parallel transcriptional profiling of the atherosclerotic arterial wall identified 37 cholesterol-responsive genes mediating this effect. Validation by siRNA-inhibition in macrophages incubated with acetylated-LDL revealed a network of eight cholesterol-responsive atherosclerosis genes regulating cholesterol-ester accumulation. Taken together, we have identified a network of atherosclerosis genes that in response to plasma cholesterol-lowering prevents the formation of advanced plaques. This network should be of interest for the development of novel atherosclerosis therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.